Adaptive Biotechnologies (NASDAQ: ADPT) reported Q4 EPS of ($0.33), $0.04 worse than the analyst estimate of ($0.29). Revenue for the quarter came in at $30.2 million versus the consensus estimate of $26.9 million.

"Adaptive's launch of T-Detect COVID marks a pivotal moment in the diagnostic testing paradigm. We have now proven that it is possible to read how T cells detect disease in the blood and we are on a fast path to develop this product for many other indications," said Chad Robins, chief executive officer and co-founder of Adaptive Biotechnologies. "As we move into 2021, we are poised to execute on several key catalysts across all business areas that will accelerate our vision to power the age of immune medicine."

For earnings history and earnings-related data on Adaptive Biotechnologies (ADPT) click here.